Drug data last refreshed 13h ago · AI intelligence enriched 2w ago
PYLORI-CHEK BREATH TEST is a diagnostic agent containing urea labeled with carbon-13 isotope, administered orally as a solution to detect Helicobacter pylori infection. The test measures C-13 in exhaled breath to confirm active H. pylori colonization in the stomach. It is a non-invasive diagnostic tool rather than a therapeutic agent.
As a diagnostic product approaching loss of exclusivity with moderate competitive pressure (30%), the brand team may face downsizing or transition to defend niche market segments.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
With zero linked job postings and approaching LOE, career growth in PYLORI-CHEK roles is limited; positions are typically in diagnostics-focused teams managing reimbursement, physician education, and competitive defense rather than commercial expansion. Professionals joining this product should expect stable, specialized work in a mature market with limited upward mobility.
Worked on PYLORI-CHEK BREATH TEST at GT Metabolic Solutions? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.